‘Real-life’ experience in asthmatic children treated with omalizumab up to six-years follow-up
Main Article Content
Keywords
Omalizumab, Pediatric asthma, ‘Real-life’
Abstract
Introduction and objectives: Omalizumab is present in international guidelines for the control of severe asthma, but data on the long-term effects in children are limited. Our objective was to perform a ‘real-life’ long-term trial of omalizumab in children with allergic asthma.
Materials and methods: An observational single center ‘real-life’ study was performed. Data for treatment, lung function, side effect, asthma exacerbations and hospitalizations were recorded at six months and annually.
Results: Forty-eight patients <18 years of age were enrolled. Median treatment period was 2.9 (0.5-6). Fluticasone dose for the maintenance treatment decreases significantly at six months (452 mcg/day to 329.89 mcg/day, respectively). This difference was maintained throughout the follow-up. Nobody used oral corticosteroid after six months. The rate of hospital admissions and visits to the emergency department for asthma exacerbations decreased significantly in the third years and fourth years follow-up, respectively. There was an improvement in lung function. Mean values of FEV1 and FEF25-75% before treatment were 79.88 and 62.94, respectively; after six months of treatment a statistically significant change was seen with a mean FEV1 of 92.29 and FEF25-75% of 76.31 (p = 0.0001). Lung function values were above normal throughout the six years of treatment. No side effects were reported.
Conclusions: Overall in ‘real life’ omalizumab in children reduces asthma exacerbations and hospitalizations, improves lung function, and decreases the maintenance therapy. It is shown to be safe for up to six years of treatment in children.
References
2. Carvajal-Urena˜ I, García-Marcos L, Busquets-Monge R, Morales Suárez-Varela M, García de Andoin N, Batlles-Garrido A, et al. Geographic variation in the prevalence of ashtma symptoms in Spanish children and adolescents International Study of Asthma and Allergies inh Childhood (ISAAC) Phase3. Spain. Arch Bronconeumol. 2005;41:659-66.
3. Plaza AM, Ibánez ˜ MD, Sánchez-Solís M, Bosque-García M, Cabero MJ, Corzo JL, et al. Consenso para el abordaje del asma pediátrica en la práctica clínica habitual. An Pediatr. 2016;84, 122.e1-122.e11.
4. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012;67:976-97.
5. Guía espanola ˜ para el manejo del asma, 2015 (GEMA 4.0).
6. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90.
7. Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.
8. Buhl 1, Solèr M, Matz J, Townley R, O’Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate to severe allergic asthma. Eur Respir J. 2002;20:73-8.
9. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154-9.
10. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2013;111:278-84.
11. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-17.
12. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102:1371-8.
13. Molimard M, De blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair® ) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71-6.
14. Bousquet J, Siergiejko Z, Wiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671-8.
15. Braunstahl G, Chlumsky J, Peachey G, Chen CW. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol. 2013;9:47.
16. Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143:398-405.
17. Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, et al. Asthma control in severe asthmatics under treatment with omaliuzmab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123-9.
18. Casan P, Roca J, Sanchis J. Spirometric response to bronchodilator. Reference values for healthy children and adolescents. Bull Eur Physiopathol Respir. 1983;19:567-9.
19. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: 1-year real life survey. Eur Respir J. 2013;42:1224-33.
20. Deschildre A, Marguet C, Langlois C, Pin I, Rittié JL, Derelle J, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Resp J. 2015;46:856-9.
21. Pitrez P, De Souza R, Roncada C, Heinzmann-Filho JP, Santos G, Pinto LA, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life. Pediatr Pulmonol. 2017;52: 1-2.
22. Licari A, Castagnoli R, Denicolo C, Rossini L, Seminara M, Sacchi L, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13:36-42.
23. Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, et al. Omalizumab in Japanese children with severe asthma uncontrolled with standard therapy. Allergol Int. 2015;64:364-70.
24. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with ant-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108:E36.
25. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. New Engl J Med. 2011;364: 1005-15.
26. Brodlie M, Mc Kean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97: 604-9.
27. Hossny E, Rosario N, Lee BW, Singh M, El-Ghoneimy D, Soh JY, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J. 2016;9:26.
28. Leung J, Johson D, Sperou A, Crotts J, Saude E, Hartling L, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. PLOS ONE. 2017, http://dx.doi.org/10.1371/journal.pone.0182738. Date last accessed: March 2018.
29. Stelmach I, Majak P, Jerzynska J, Bojo M, Cichalewski Ł, Smejda K, et al. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series form Poland. Arch Med Sci. 2015;11: 901-4.
30. Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26:551-6.
31. Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K, et al. ‘Real-life’ effectiveness studies of omalizumab in adults patients with severe allergic asthma: systematic review. Allergy. 2016;71:593-610.
32. Romano C. Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Rev Clin Immunol. 2015;11:1309-19.
33. Ledford D, Busse W, Trzaskoma MS, Omachi TA, Rosén K, Chipps BE, et al. A randomized multicenter study evaluating Xolair persistency of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162-9.
34. Molimard M, Mala L, Bourdeix I, Le Gros V, et al. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108: 571-6.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.